Qiagen Launches Digital PCR Assay Design Tool For QIAcuity, Expands Customization Capabilities Of Its Research Platform GeneGlobe
Author: Benzinga Newsdesk | June 05, 2024 04:25pm
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a comprehensive research platform that integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs, and pathways. The new advancements aim to support customers with a wide range of assay customization options, from simple to complex and validated multiplex assays, while further improving the user experience.
Posted In: QGEN